Type I and Type II photosensitization of DNA etheno adducts.

Photophysical and photochemical studies were carried out to examine the photoreactivity of etheno adducts, 1,N-ethenoadenine (εdA) and 1,N-ethenoguanine (εdG), in the presence of two well-known photosensitizers acting by Type I and/or Type II mechanisms such as 4-carboxybenzophenone (CBP) and rose Bengal (RB), respectively. Steady-state photolysis experiments combined with HPLC and mass spectroscopy measurements lead to photoproducts that correspond to the repaired nucleosides. To determine the mechanism of this photooxidation processes, phosphorescence spectroscopy, direct detection of singlet oxygen luminescence and laser flash photolysis were carried out.

FVIII peptides presented on HLA-DP and identification of an A3 domain peptide binding with high affinity to the commonly expressed HLA-DP4.

The development of neutralizing antibodies (inhibitors) against coagulation factor VIII (FVIII) poses a major challenge in hemophilia A (HA) treatment. The formation of FVIII inhibitors is a CD4+ T-cell dependent mechanism which includes antigen presenting cells (APCs), B- and T-helper lymphocytes. APCs present FVIII derived peptides on major histocompatibility complex class II (MHC-II) to CD4+ Tcells.

Protein nanoparticle vaccines induce potent neutralizing antibody responses against MERS-CoV.

Middle East respiratory syndrome coronavirus (MERS-CoV) is a betacoronavirus that causes severe respiratory illness in humans. There are no licensed vaccines against MERS-CoV and only a few candidates in phase I clinical trials. Here, we develop MERS-CoV vaccines utilizing a computationally designed protein nanoparticle platform that has generated safe and immunogenic vaccines against various enveloped viruses, including a licensed vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

miR-449, identified through antiandrogen exposure, mitigates functional biomarkers associated with ovarian cancer risk.

The involvement of the androgen receptor (AR) pathway in developing epithelial ovarian cancer is increasingly acknowledged. However, the specific mechanisms by which anti-androgen agents, such as flutamide, may prevent ovarian cancer and their efficacy remain unknown. This study was initiated by investigating the impact of flutamide on miRNA expression in women at high risk (HR) for ovarian cancer.